Credit Suisse’s Elicio Therapeutics ELTX Stock Holding History

Credit Suisse’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1	Closed	–	–	4096
2022 Q2	$0	Buy	+1	New	+$16	﹤0.01%	4023

Other funds holding ELTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Credit Suisse's ELTX Position: Q3 2022 in Review

Credit Suisse sold out of Elicio Therapeutics (ELTX) in Q3 2022, closing a stake of 1 share.

Credit Suisse first reported a position in ELTX in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 38 funds tracked by Wall St. Rank hold ELTX as of Q3 2022.

Credit Suisse reported no remaining Elicio Therapeutics position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 1 Elicio Therapeutics share in Q3 2022.
Credit Suisse first reported a position in Elicio Therapeutics in Q2 2022 and held it in 1 quarter.
Credit Suisse's Elicio Therapeutics position peaked at $0 in Q2 2022.
38 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.